Molecular Approach to Allergy Diagnosis and Therapy

키워드

참고문헌 (90)

1. Kay AB, "Allergy and allergic diseases. Second of two parts", N Engl J Med, 344, pp.109~113 (2001)
2. Kay AB, "Allergy and allergic diseases. First of two parts", N Engl J Med, 344, pp.30~37 (2001)
3. Masoli M, "The global burden of asthma: executive summary of the GINA Dissemination Committee report", Allergy, 59, pp.469~478 (2004)
4. Ferreira F, "Modified recombinant allergens for safer immunotherapy", Inflamm Allergy Drug Targets, 5, pp.5~14 (2006)
5. Valenta R, "Recombinant allergens for immunotherapy", J Allergy Clin Immunol, 119, pp.826~830 (2007)
6. Akdis M, "Mechanisms of allergen-specific immunotherapy", J Allergy Clin Immunol, 119, pp.780~791 (2007)
7. Larché M, "Immunological mechanisms of allergen-specific immunotherapy", Nat Rev Immunol, 6, pp.761~771 (2006)
8. Jutel M, "Allergen-specific immunotherapy with recombinant grass pollen allergens", J Allergy Clin Immunol, 116, pp.608~613 (2005)
9. Niederberger V, "Vaccination with genetically engineered allergens prevents progression of allergic disease", Proc Natl Acad Sci U S A, 101(Suppl 2), pp.14677~14682 (2004)
10. Tulic MK, "Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response", J Allergy Clin Immunol, 113, pp.235~241 (2004)
11. Moingeon P, "Immune mechanisms of allergen-specific sublingual immunotherapy", Allergy, 61, pp.151~165 (2006)
12. Weiss R, "Design of protective and therapeutic DNA vaccines for the treatment of allergic diseases", Curr Drug Targets Inflamm Allergy, 4, pp.585~597 (2005)
13. Weiss R, "Is genetic vaccination against allergy possible?", Int Arch Allergy Immunol, 139, pp.332~345 (2006)
14. van Ree R, "The CREATE project: EU support for the improvement of allergen standardization in Europe", Allergy, 59, pp.571~574 (2004)
15. Akkerdaas JH, "How accurate and safe is the diagnosis of hazelnut allergy by means of commercial skin prick test reagents?", Int Arch Allergy Immunol, 132, pp.132~140 (2003)
16. Curin M, "Skin prick test extracts for dog allergy diagnosis show considerable variations regarding the content of major and minor dog allergens", Int Arch Allergy Immunol, 154, pp.258~263 (2011)
17. "Standardized Allergenic Extracts" (2009)[URL]
18. 정경용, "Optimization of Allergen Standardization", Yonsei Medical Journal, 52(3), pp.393~400 (2011), 연세대학교의과대학
19. van Ree R, "The CREATE project: development of certified reference materials for allergenic products and validation of methods for their quantification", Allergy, 63, pp.310~326 (2008)
20. "EDQM Annual Report 2011" (2011)[URL]
21. Vieths S, "Establishment of recombinant major allergens Bet v 1 and Phl p 5a as Ph. Eur. reference standards and validation of ELISA methods for their measurement. Results from feasibility studies", Pharmeur Bio Sci Notes, 2012, pp.118~134 (2012)
22. Himly M, "Standardization of allergen products: 1. Detailed characterization of GMP-produced recombinant Bet v 1.0101 as biological reference preparation", Allergy, 64, pp.1038~1045 (2009)
23. Canonica GW, "A WAO-ARIA- GA²LEN consensus document on molecular-based allergy diagnostics", World Allergy Organ J, 6, pp.17~ (2013)
24. Westritschnig K, "Different allergenic activity of grass pollen allergens revealed by skin testing", Eur J Clin Invest, 38, pp.260~267 (2008)
25. Tripodi S, "Molecular profiles of IgE to Phleum pratense in children with grass pollen allergy: implications for specific immunotherapy", J Allergy Clin Immunol, 129, pp.834~839 (2012)
26. Gadermaier G, "Allergens of weed pollen: an overview on recombinant and natural molecules", Methods, 66, pp.55~66 (2014)
27. Asero R, "Artemisia and Ambrosia hypersensitivity: co-sensitization or co-recognition?", Clin Exp Allergy, 36, pp.658~665 (2006)
28. Gadermaier G, "Array-based profiling of ragweed and mugwort pollen allergens", Allergy, 63, pp.1543~1549 (2008)
29. Müller UR, "Hymenoptera venom allergy: analysis of double positivity to honey bee and Vespula venom by estimation of IgE antibodies to species-specific major allergens Api m1 and Ves v5", Allergy, 64, pp.543~548 (2009)
30. Hemmer W, "Antibody binding to venom carbohydrates is a frequent cause for double positivity to honeybee and yellow jacket venom in patients with stinging-insect allergy", J Allergy Clin Immunol, 108, pp.1045~1052 (2001)
31. Müller U, "IgE to recombinant allergens Api m 1, Ves v 1, and Ves v 5 distinguish double sensitization from crossreaction in venom allergy", Allergy, 67, pp.1069~1073 (2012)
32. Shreffler WG, "Microarrayed recombinant allergens for diagnostic testing", J Allergy Clin Immunol, 127, pp.843~849 (2011)
33. Arbes SJ Jr, "Prevalences of positive skin test responses to 10 common allergens in the US population: results from the third National Health and Nutrition Examination Survey", J Allergy Clin Immunol, 116, pp.377~383 (2005)
34. Codreanu F, "A novel immunoassay using recombinant allergens simplifies peanut allergy diagnosis", Int Arch Allergy Immunol, 154, pp.216~226 (2011)
35. Cromwell O, "Recombinant allergens for specific immunotherapy", J Allergy Clin Immunol, 127, pp.865~872 (2011)
36. (2013)[URL]
37. "ImmunoCAP Allergen list" (2013)[URL]
38. Javaloyes G, "Performance of different in vitro techniques in the molecular diagnosis of peanut allergy", J Investig Allergol Clin Immunol, 22, pp.508~513 (2012)
39. Wöhrl S, "The performance of a component-based allergen-microarray in clinical practice", Allergy, 61, pp.633~639 (2006)
40. Ebo DG, "Sensitization profiles in birch pollen-allergic patients with and without oral allergy syndrome to apple: lessons from multiplexed component-resolved allergy diagnosis", Clin Exp Allergy, 40, pp.339~347 (2010)
41. Villalta D, "Is the detection of IgE to multiple Bet v 1-homologous food allergens by means of allergen microarray clinically useful?", J Allergy Clin Immunol, 125, pp.1158~1161 (2010)
42. Bublin M, "The performance of a component-based allergen microarray for the diagnosis of kiwifruit allergy", Clin Exp Allergy, 41, pp.129~136 (2011)
43. Nicolaou N, "Allergy or tolerance in children sensitized to peanut: prevalence and differentiation using component-resolved diagnostics", J Allergy Clin Immunol, 125, pp.191~197 (2010)
44. Ebo DG, "Component-resolved diagnosis from latex allergy by microarray", Clin Exp Allergy, 40, pp.348~358 (2010)
45. Sastre J, "How molecular diagnosis can change allergen-specific immunotherapy prescription in a complex pollen area", Allergy, 67, pp.709~711 (2012)
46. Andersson K, "Characteristics and immunobiology of grass pollen allergens", Int Arch Allergy Immunol, 130, pp.87~107 (2003)
47. Sekerkova A, "Detection of Phl p 1, Phl p 5, Phl p 7 and Phl p 12 specific IgE antibodies in the sera of children and adult patients allergic to Phleum pollen", Allergol Int, 61, pp.339~346 (2012)
48. Thomas WR, "House dust mite allergens in asthma and allergy", Trends Mol Med, 16, pp.321~328 (2010)
49. Pauli G, "Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis", J Allergy Clin Immunol, 122, pp.951~960 (2008)
50. Larenas-Linnemann D, "Oralair Birch, a recombinant major birch pollen allergen tablet for sublingual immunotherapy of allergic rhinitis caused by birch pollen", Curr Opin Investig Drugs, 11, pp.586~596 (2010)
51. Klimek L, "Specific subcutaneous immunotherapy with recombinant grass pollen allergens: first randomized dose-ranging safety study", Clin Exp Allergy, 42, pp.936~945 (2012)
52. Vrtala S, "Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy", J Clin Invest, 99, pp.1673~1681 (1997)
53. Vrtala S, "Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen Bet v 1", FASEB J, 15, pp.2045~2047 (2001)
54. Purohit A, "Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives", Clin Exp Allergy, 38, pp.1514~1525 (2008)
55. Kahlert H, "Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy", Int Arch Allergy Immunol, 145, pp.193~206 (2008)
56. Meyer W, "Double-blind, placebo-controlled, dose-ranging study of new recombinant hypoallergenic Bet v 1 in an environmental exposure chamber", Allergy, 68, pp.724~731 (2013)
57. Zuidmeer-Jongejan L, "FAST: towards safe and effective subcutaneous immunotherapy of persistent life-threatening food allergies", Clin Transl Allergy, 2, pp.5~ (2012)
58. Stanley JS, "Identification and mutational analysis of the immunodominant IgE binding epitopes of the major peanut allergen Ara h 2", Arch Biochem Biophys, 342, pp.244~253 (1997)
59. Burks AW, "Mapping and mutational analysis of the IgE-binding epitopes on Ara h 1, a legume vicilin protein and a major allergen in peanut hypersensitivity", Eur J Biochem, 245, pp.334~339 (1997)
60. Wood RA, "A phase 1 study of heat", phenol-killed, E. coli-encapsulated, recombinant modified peanut proteins Ara h 1, Ara h 2, and Ara h 3 (EMP-123) for the treatment of peanut allergy, 2013, pp.68, 803~808
61. Moldaver D, "Immunotherapy with peptides", Allergy, 66, pp.784~791 (2011)
62. Fellrath JM, "Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: results of a phase I trial", J Allergy Clin Immunol, 111, pp.854~861 (2003)
63. Pellaton C, "Novel birch pollen specific immunotherapy formulation based on contiguous overlapping peptides", Clin Transl Allergy, 3, pp.17~ (2013)
64. Marth K, "A nonallergenic birch pollen allergy vaccine consisting of hepatitis PreS-fused Bet v 1 peptides focuses blocking IgG toward IgE epitopes and shifts immune responses to a tolerogenic and Th1 phenotype", J Immunol, 190, pp.3068~3078 (2013)
65. Twaroch TE, "Carrier-bound, nonallergenic Ole e 1 peptides for vaccination against olive pollen allergy", J Allergy Clin Immunol, 128, pp.178~184 (2011)
66. Focke M, "Developments in allergen-specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen-specific immunoglobulin E and T cell reactivity", Clin Exp Allergy, 40, pp.385~397 (2010)
67. Worm M, "Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy", J Allergy Clin Immunol, 127, pp.89~97 (2011)
68. Patel D, "Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study", J Allergy Clin Immunol, 131, pp.103~109 (2013)
69. Müller U, "Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom", J Allergy Clin Immunol, 101(6 Pt 1), pp.747~754 (1998)
70. Hauser M, "Bet v 1-like pollen allergens of multiple Fagales species can sensitize atopic individuals", Clin Exp Allergy, 41, pp.1804~1814 (2011)
71. Jahn-Schmid B, "Allergen microarray: comparison of microarray using recombinant allergens with conventional diagnostic methods to detect allergen-specific serum immunoglobulin E", Clin Exp Allergy, 33, pp.1443~1449 (2003)
72. Cabrera-Freitag P, "Can component-based microarray replace fluorescent enzimoimmunoassay in the diagnosis of grass and cypress pollen allergy?", Clin Exp Allergy, 41, pp.1440~1446 (2011)
73. Bronnert M, "Component-resolved diagnosis with commercially available D. pteronyssinus Der p 1, Der p 2 and Der p 10: relevant markers for house dust mite allergy", Clin Exp Allergy, 42, pp.1406~1415 (2012)
74. Ott H, "Clinical usefulness of microarray-based IgE detection in children with suspected food allergy", Allergy, 63, pp.1521~1528 (2008)
75. D’Urbano LE, "Performance of a component-based allergen-microarray in the diagnosis of cow’s milk and hen’s egg allergy", Clin Exp Allergy, 40, pp.1561~1570 (2010)
76. Alessandri C, "Ovomucoid (Gal d 1) specific IgE detected by microarray system predict tolerability to boiled hen’s egg and an increased risk to progress to multiple environmental allergen sensitisation", Clin Exp Allergy, 42, pp.441~450 (2012)
77. Hofmann SC, "IgE detection to α", β, Allergy, pp.2012, 67[DOI]
78. Berneder M, "Allergen chip diagnosis for soy-allergic patients: Gly m 4 as a marker for severe food-allergic reactions to soy", Int Arch Allergy Immunol, 161, pp.229~233 (2013)
79. Schuler S, "Microarray-based component-resolved diagnosis of latex allergy: isolated IgE-mediated sensitization to latexprofilin Hev b8 may act as confounder", Clin Transl Allergy, 3, pp.11~ (2013)
80. Ott H, "Microarrays of recombinant Hevea brasiliensis proteins: a novel tool for the component-resolved diagnosis of natural rubber latex allergy", J Investig Allergol Clin Immunol, 20, pp.129~138 (2010)
81. Winther L, "Safety and tolerability of recombinant Bet v 1 (rBet v 1) tablets in sublingual immunotherapy (SLIT)", J Allergy Clin Immunol, 123(Suppl), pp.S215~ (2009)
82. Reisinger J, "Allergen-specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity", J Allergy Clin Immunol, 116, pp.347~354 (2005)
83. Niederberger V, "Vaccination with genetically modified birch pollen allergens: immune and clinical effects on oral allergy syndrome", J Allergy Clin Immunol, 119, pp.1013~1016 (2007)
84. Pree I, "Inhibition of CD23-dependent facilitated allergen binding to B cells following vaccination with genetically modified hypoallergenic Bet v 1 molecules", Clin Exp Allergy, 40, pp.1346~1352 (2010)
85. Pauli G, "Comparison of genetically engineered hypoallergenic rBet v 1 derivatives with rBet v 1 wild-type by skin prick and intradermal testing: results obtained in a French population", Clin Exp Allergy, 30, pp.1076~1084 (2000)
86. Senti G, "Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections", J Allergy Clin Immunol, 129, pp.1290~1296 (2012)
87. Zhang K, "Chimeric human fcgamma-allergen fusion proteins in the prevention of allergy", Immunol Allergy Clin North Am, 27, pp.93~103 (2007)
88. Maguire P, "The safety and efficacy of ALLERVAX CAT in cat allergic patients", Clin Immunol, 93, pp.222~231 (1999)
89. Alexander C, "The effect of Fel d 1-derived T-cell peptides on upper and lower airway outcome measurements in cat-allergic subjects", Allergy, 60, pp.1269~1274 (2005)
90. Kündig TM, "Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults", J Allergy Clin Immunol, 117, pp.1470~1476 (2006)

관련 논문AI추천